Chordate Medical signs new joint venture agreement with Nanos Medical in Shanghai

6 December, 2021

Chordate Medical (publ) ("Chordate" or "the Company") and the Chinese medtech company Nanos Medical have entered into a renewed joint venture agreement governing the cooperation of the jointly owned company Changyong Medical Technology Co. which will market Chordate's treatment method for rhinitis, chronic nasal congestion, in the Chinese market. Nanos Medical, which invests all working capital in the jointly owned company, estimates the schedule for obtaining the market license to be at least 16 months.

Chordate and Nanos Medical started a joint venture in 2018 and then formed a jointly owned company in Shanghai with the intention of marketing the K.O.S technology in the Chinese market. Nanos Medical owns 2/3 of this company, Changyong Medical Technology Co., and is the party that finances marketing and sales, Chordate will for its 1/3 submit the Chinese patents when product registration is in place.

In August, Chordate received a prepaid order for two new-generation K.O.S. machines which has since been delivered to Changyong Medical Technology Co. Ltd. The K.O.S machines are used in the work to obtain a national market permit for Chordate's technology for rhinitis treatment. The registration work is ongoing.

“This means that we still have a capital-strong partner in China who believes in and invests in the K.O.S treatment for rhinitis. Nanos Medical is said to be the Number One actor on the Ear/Nose/Throat-market in China”, says Anders Weilandt, CEO of Chordate Medical.

This disclosure contains information that Chordate Medical Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person below, on December 6th, 2021, at 15:00 a.m. CET.

For more information, please contact:
Anders Weilandt
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel, and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM - SME (ticker: CMH). Read more at

Fler Nyheter

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate's share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of the K.O.S treatment, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.


Contact us

The information is handled according to our  privacy policy.